WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2012109203) ADJUVANT COMPOSITIONS WITH 4-IBBL
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/109203    International Application No.:    PCT/US2012/024092
Publication Date: 16.08.2012 International Filing Date: 07.02.2012
IPC:
A61K 39/39 (2006.01), A61K 47/06 (2006.01)
Applicants: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. [US/US]; Health Science Center Room 321 University Of Louisville Louisville, KY 40292 (US) (For All Designated States Except US).
SHIRWAN, Haval [US/US]; (US) (For US Only)
Inventors: SHIRWAN, Haval; (US)
Agent: BRINCKERHOFF, Courtenay, C.; Foley & Lardner Llp 3000 K Street Nw Washington, DC 20007 (US)
Priority Data:
61/441,392 10.02.2011 US
Title (EN) ADJUVANT COMPOSITIONS WITH 4-IBBL
(FR) COMPOSITIONS D'ADJUVANT AVEC 4-1BBL
Abstract: front page image
(EN)Streptavidin(SA)-4-lBBL and TLR agonists such as monophosphoryl lipid A (MPL) exhibit surprising synergy as adjuvants, inducing immune responses against weak antigens. Accordingly, there are provided adjuvant compositions comprising 4-lBBL and a toll-like receptor (TLR) agonist, such as MPL, methods of inducing an immune response against an antigen in a subject, comprising administering to the subject (a) the antigen, (b) a TLR agonist and, (c) 4-lBBL, and methods of treating a tumor or a cancer in a subject, comprising administering to the subject (a) an antigen associated with the tumor or cancer, (b) a TLR agonist, and (c) 4-lBBL.
(FR)La streptavidine (SA)-4-lBBL et des agonistes de TLR comme le monophosphoryl lipide A (MPL) présentent une synergie surprenante en tant qu'adjuvants, en induisant des réponses immunitaires contre des antigènes faibles. Par conséquent, l'invention concerne des compositions d'adjuvant comprenant 4-lBBL et un agoniste de récepteur de type Toll (TLR), comme MPL, des procédés d'induction d'une réponse immunitaire contre un antigène dans un sujet, comprenant l'administration au sujet (a) de l'antigène, (b) d'un agoniste de TLR et (c) de 4-1BBL, et des procédés de traitement d'une tumeur ou d'un cancer chez un sujet, comprenant l'administration au sujet (a) d'un antigène associé à la tumeur ou au cancer, (b) d'un agoniste de TLR et (c) de 4-1BBL.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)